Shares of Axsome Therapeutics surged 6.9% to $237.40 after the company announced it has now settled all outstanding patent litigation over its wakefulness drug, solriamfetol — a medicine for excessive daytime sleepiness tied to narcolepsy and sleep apnea. The final settlement removes the last legal cloud hanging over a product generating roughly 20% of the company's revenue, giving investors a clearer picture of cash flows stretching more than a decade into the future.
Three Settlements in Thirteen Months Seal Off Generic Threats Until 2040. Axsome settled with Hikma Pharmaceuticals in March 2025 , followed by Hetero Labs , and then Alkem Laboratories in February 2026 . Every deal carries near-identical terms: generics cannot launch before March 1, 2040 — or September 1, 2040 if pediatric exclusivity is granted.
The company's IP portfolio now extends protection to at least 2042 for the drug. That gives Axsome roughly 14 years of brand-only pricing power on a medication that currently costs about $1,100–$1,230 per month without insurance.
A $125 Million Product With Room to Expand — Or Disappoint. Solriamfetol generated $124.8 million in full-year 2025 revenue , and contributed $33.9 million in Q1 2026, up 34% year-over-year. But the drug's bigger upside lies in pipeline expansion: Axsome is running late-stage trials in binge eating disorder, shift work disorder, ADHD, and depression with sleepiness symptoms.
The company projects its full portfolio could generate over $18 billion in peak sales — an ambitious target for a firm with a ~$10.6 billion market cap.
Legal Clarity Arrives, but the Balance Sheet Still Needs Watching. Axsome ended Q1 2026 with $305 million in cash against $190 million in debt , while spending $185 million on sales and general expenses in just one quarter — a 53% jump as it expands its sales force. The company recently grew its salesforce to about 600 representatives ahead of a potential Alzheimer's agitation approval. Clearing the patent disputes eliminates legal costs and distractions, but the real test is whether solriamfetol's new indications can convert into revenue before cash runs thin.
Bottom line: The settlement spree locks in a long runway of exclusivity, but investors are now paying for execution — not just protection.